Citadel Advisors
VIRX

Citadel Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Citadel Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,626,258
Closed -$262K – 15998
2024
Q4 		$262K Buy
1,626,258
+106,018
+7% +$20.9K ﹤0.01% 9937
2024
Q3 		$352K Hold
1,520,240
– – ﹤0.01% 8986
2024
Q2 		$827K Sell
1,520,240
-44,962
-3% -$35.5K ﹤0.01% 6989
2024
Q1 		$1.6M Buy
1,565,202
+36,130
+2% +$26.4K ﹤0.01% 5961
2023
Q4 		$872K Buy
1,529,072
+8,668
+0.6% +$5.32K ﹤0.01% 6948
2023
Q3 		$1.58M Buy
1,520,404
+61
+0% +$83 ﹤0.01% 5655
2023
Q2 		$2.14M Sell
1,520,343
-36,980
-2% -$52.9K ﹤0.01% 5034
2023
Q1 		$2.48M Buy
1,557,323
+3,644
+0.2% +$6.62K ﹤0.01% 4979
2022
Q4 		$2.27M Sell
1,553,679
-8,336
-0.5% -$24.3K ﹤0.01% 5239
2022
Q3 		$6.67M Buy
1,562,015
+5,793
+0.4% +$24.5K ﹤0.01% 3400
2022
Q2 		$6.04M Sell
1,556,222
-8,792
-0.6% -$25K ﹤0.01% 3461
2022
Q1 		$7.45M Buy
1,565,014
+29,185
+2% +$87.9K ﹤0.01% 3449
2021
Q4 		$5.61M Sell
1,535,829
-2,533
-0.2% -$13.5K ﹤0.01% 4099
2021
Q3 		$12.3M Buy
1,538,362
+6,504
+0.4% +$64.1K ﹤0.01% 2714
2021
Q2 		$17.4M Buy
1,531,858
+8,346
+0.5% +$83.7K ﹤0.01% 2261
2021
Q1 		$14.1M Buy
1,523,512
+1,514,595
+16,985% +$15.8M ﹤0.01% 2466
2020
Q4 		$62K Sell
8,917
-144,094
-94% -$752K ﹤0.01% 10488
2020
Q3 		$669K Buy
153,011
+43,078
+39% +$376K ﹤0.01% 6773
2020
Q2 		$1.01M Buy
109,933
+6,969
+7% +$105K ﹤0.01% 5803
2020
Q1 		$1.5M Buy
102,964
+102,487
+21,486% +$2.22M ﹤0.01% 4629
2019
Q4 		$6K Sell
477
-103
-18% -$1.73K ﹤0.01% 9020
2019
Q3 		$15K Sell
580
-260
-31% -$7.5K ﹤0.01% 9001
2019
Q2 		$21K Sell
840
-8,300
-91% -$321K ﹤0.01% 8941
2019
Q1 		$389K Buy
9,140
+8,396
+1,128% +$190K ﹤0.01% 7204
2018
Q4 		$11K Buy
+744
New +$30.4K ﹤0.01% 8915
2018
Q3 		– Sell
-485
Closed -$36.8K – 9805
2018
Q2 		$36K Buy
+485
New +$43.2K ﹤0.01% 8513
2016
Q2 		– Sell
-132
Closed -$14.6K – 7522
2016
Q1 		$15K Buy
132
+56
+74% +$8.49K ﹤0.01% 6547
2015
Q4 		$14K Buy
76
+8
+12% +$1.5K ﹤0.01% 8154
2015
Q3 		$12K Buy
68
+22
+48% +$7.94K ﹤0.01% 8410
2015
Q2 		$29K Sell
46
-463
-91% -$246K ﹤0.01% 7984
2015
Q1 		$262K Sell
509
-11,756
-96% -$5.93M ﹤0.01% 5840
2014
Q4 		$6.57M Sell
12,265
-3,250
-21% -$1.46M 0.01% 1731
2014
Q3 		$23.3M Buy
15,515
+15,146
+4,105% +$21.9M 0.02% 823
2014
Q2 		$504K Buy
369
+290
+367% +$336K ﹤0.01% 4380
2014
Q1 		$109K Buy
+79
New +$91.9K ﹤0.01% 6121

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Citadel Advisors's VIRX Position: Q1 2025 in Review

Citadel Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 1,626,258 shares — an estimated $262K sold.

Citadel Advisors first reported a position in VIRX in Q1 2014 and held it in 35 quarters. The position peaked at $23.3M in Q3 2014. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • Citadel Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 1,626,258 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $262K.
  • Citadel Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2014 and held it in 35 quarters.
  • Citadel Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $23.3M in Q3 2014.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.